

# Claes Wahlestedt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9322383/publications.pdf>

Version: 2024-02-01

233  
papers

24,171  
citations

8181

76  
h-index

7745

150  
g-index

250  
all docs

250  
docs citations

250  
times ranked

29814  
citing authors

#	ARTICLE	IF	CITATIONS
1	A novel strategy for combination of clofarabine and pictilisib is synergistic in gastric cancer. <i>Translational Oncology</i> , 2022, 15, 101260.	3.7	3
2	JOTROL, a Novel Formulation of Resveratrol, Shows Beneficial Effects in the 3xTg-AD Mouse Model. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 173-190.	2.6	7
3	A human-based multi-gene signature enables quantitative drug repurposing for metabolic disease. <i>ELife</i> , 2022, 11, .	6.0	9
4	DOT1L Is a Novel Cancer Stem Cell Target for Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1948-1965.	7.0	21
5	Direct Administration and Gene Modulation Using Antisense Oligonucleotides Within the CNS. <i>Cellular and Molecular Neurobiology</i> , 2021, 41, 849-853.	3.3	1
6	Dual Screen for Efficacy and Toxicity Identifies HDAC Inhibitor with Distinctive Activity Spectrum for BAP1-Mutant Uveal Melanoma. <i>Molecular Cancer Research</i> , 2021, 19, 215-222.	3.4	21
7	Dysregulation of the histone demethylase KDM6B in alcohol dependence is associated with epigenetic regulation of inflammatory signaling pathways. <i>Addiction Biology</i> , 2021, 26, e12816.	2.6	28
8	Alcohol use disorder causes global changes in splicing in the human brain. <i>Translational Psychiatry</i> , 2021, 11, 2.	4.8	25
9	Sexual Dimorphism in the 3xTg-AD Mouse Model and Its Impact on Pre-Clinical Research. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 41-52.	2.6	35
10	Nucleic Acid-Based Therapeutics in Orphan Neurological Disorders: Recent Developments. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 643681.	3.5	10
11	A novel knockout mouse model of the noncoding antisense Brain-Derived Neurotrophic Factor (Bdnf) gene displays increased endogenous Bdnf protein and improved memory function following exercise. <i>Heliyon</i> , 2021, 7, e07570.	3.2	4
12	Epigenetic Small Molecules Rescue Nucleocytoplasmic Transport and DNA Damage Phenotypes in C9ORF72 ALS/FTD. <i>Brain Sciences</i> , 2021, 11, 1543.	2.3	5
13	Molecular mechanisms of psychiatric diseases. <i>Neurobiology of Disease</i> , 2020, 146, 105136.	4.4	21
14	Genome-Wide Effects of Alcohol Use Disorder on Long Non-Coding RNAs and Splicing in Brain and Liver. <i>Biological Psychiatry</i> , 2020, 87, S178-S179.	1.3	0
15	Molecular Transducers of Human Skeletal Muscle Remodeling under Different Loading States. <i>Cell Reports</i> , 2020, 32, 107980.	6.4	30
16	Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734. <i>Blood Advances</i> , 2020, 4, 4124-4135.	5.2	37
17	Benefits of a novel highly bioavailable resveratrol formulation, JOTROL, for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e046267.	0.8	2
18	Dipeptide repeat proteins inhibit homology-directed DNA double strand break repair in C9ORF72 ALS/FTD. <i>Molecular Neurodegeneration</i> , 2020, 15, 13.	10.8	58

#	ARTICLE	IF	CITATIONS
19	Emerging Technologies for Genome-Wide Profiling of DNA Breakage. <i>Frontiers in Genetics</i> , 2020, 11, 610386.	2.3	6
20	The bromodomain inhibitor IBET-151 attenuates vismodegib-resistant esophageal adenocarcinoma growth through reduction of GLI signaling. <i>Oncotarget</i> , 2020, 11, 3174-3187.	1.8	7
21	A Neurite Outgrowth Assay and Neurotoxicity Assessment with Human Neural Progenitor Cell-Derived Neurons. <i>Journal of Visualized Experiments</i> , 2020, , .	0.3	0
22	Epigenomics of neurological disorders. , 2020, , 41-58.		0
23	Ovarian Cancer Treatment Stratification Using <i>Ex Vivo</i> Drug Sensitivity Testing. <i>Anticancer Research</i> , 2019, 39, 4023-4030.	1.1	9
24	Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis. <i>Nature Communications</i> , 2019, 10, 3126.	12.8	124
25	The novel BET/CPB/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer. <i>EMBO Molecular Medicine</i> , 2019, 11, e10659.	6.9	56
26	Longevity-related molecular pathways are subject to midlife "switch" in humans. <i>Aging Cell</i> , 2019, 18, e12970.	6.7	25
27	HDAC Inhibitors Induce BDNF Expression and Promote Neurite Outgrowth in Human Neural Progenitor Cells-Derived Neurons. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1109.	4.1	15
28	Vitamin C supplementation expands the therapeutic window of BETi for triple negative breast cancer. <i>EBioMedicine</i> , 2019, 43, 201-210.	6.1	19
29	Identification of a BET Bromodomain Inhibitor That Enables Treg Function: A Combinatorial Strategy to Inhibit GVHD. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S25-S26.	2.0	0
30	Novel approach reveals genomic landscapes of single-strand DNA breaks with nucleotide resolution in human cells. <i>Nature Communications</i> , 2019, 10, 5799.	12.8	38
31	Enhancement of BDNF Expression and Memory by HDAC Inhibition Requires BET Bromodomain Reader Proteins. <i>Journal of Neuroscience</i> , 2019, 39, 612-626.	3.6	48
32	Cocaine Exposure Increases Blood Pressure and Aortic Stiffness via the miR-30c-5p/Malic Enzyme 1 Reactive Oxygen Species Pathway. <i>Hypertension</i> , 2018, 71, 752-760.	2.7	21
33	10. Epigenetic Enzymes as Novel Therapeutic Targets in Alcohol Addiction. <i>Biological Psychiatry</i> , 2018, 83, S4.	1.3	0
34	Vitamin C Sensitizes Melanoma to BET Inhibitors. <i>Cancer Research</i> , 2018, 78, 572-583.	0.9	41
35	Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study. <i>Leukemia Research</i> , 2018, 64, 34-41.	0.8	41
36	Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies. <i>Blood</i> , 2018, 131, 328-341.	1.4	133

#	ARTICLE	IF	CITATIONS
37	Neuropeptide Y Y2 antagonist treated ovariectomized mice exhibit greater bone mineral density. <i>Neuropeptides</i> , 2018, 67, 45-55.	2.2	10
38	Inhibition of HDAC3 reverses Alzheimer's disease-related pathologies in vitro and in the 3xTg-AD mouse model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E11148-E11157.	7.1	140
39	Drug and disease signature integration identifies synergistic combinations in glioblastoma. <i>Nature Communications</i> , 2018, 9, 5315.	12.8	78
40	Purification of H3 and H4 Histone Proteins and the Quantification of Acetylated Histone Marks in Cells and Brain Tissue. <i>Journal of Visualized Experiments</i> , 2018, , .	0.3	0
41	Ex vivo drug sensitivity testing as a means for drug repurposing in esophageal adenocarcinoma. <i>PLoS ONE</i> , 2018, 13, e0203173.	2.5	6
42	Developments in lncRNA drug discovery: where are we heading?. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 837-849.	5.0	54
43	Strategies to Annotate and Characterize Long Noncoding RNAs: Advantages and Pitfalls. <i>Trends in Genetics</i> , 2018, 34, 704-721.	6.7	86
44	A coding and non-coding transcriptomic perspective on the genomics of human metabolic disease. <i>Nucleic Acids Research</i> , 2018, 46, 7772-7792.	14.5	41
45	112. Multipronged HDAC Strategy for Alzheimer's Disease. <i>Biological Psychiatry</i> , 2018, 83, S46.	1.3	0
46	Serum long noncoding RNA HOTAIR as a novel diagnostic and prognostic biomarker in glioblastoma multiforme. <i>Molecular Cancer</i> , 2018, 17, 74.	19.2	213
47	EZH1 is an antipsychotic-sensitive epigenetic modulator of social and motivational behavior that is dysregulated in schizophrenia. <i>Neurobiology of Disease</i> , 2018, 119, 149-158.	4.4	10
48	BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT. <i>Frontiers in Immunology</i> , 2018, 9, 3104.	4.8	20
49	Precision medicine in the treatment stratification of AML patients: challenges and progress. <i>Oncotarget</i> , 2018, 9, 37790-37797.	1.8	11
50	Orphan diseases: state of the drug discovery art. <i>Wiener Medizinische Wochenschrift</i> , 2017, 167, 197-204.	1.1	8
51	Oligonucleotide therapies for disorders of the nervous system. <i>Nature Biotechnology</i> , 2017, 35, 249-263.	17.5	139
52	Emerging Epigenetic Therapies in Neuroscience: Focus on Bromodomain-Containing Drug Targets. <i>Neuropsychopharmacology</i> , 2017, 42, 374-374.	5.4	3
53	Epigenetic Regulation Together with Treg Expansion: A New Combinatorial Strategy for Application in Experimental Allogeneic HSCT. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S363.	2.0	0
54	Cocaine alters Homer1 natural antisense transcript in the nucleus accumbens. <i>Molecular and Cellular Neurosciences</i> , 2017, 85, 183-189.	2.2	6

#	ARTICLE	IF	CITATIONS
55	M344 promotes nonamyloidogenic amyloid precursor protein processing while normalizing Alzheimer's disease genes and improving memory. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E9135-E9144.	7.1	50
56	The Nociceptin/Orphanin FQ receptor agonist SR-8993 as a candidate therapeutic for alcohol use disorders: Validation in rat models. <i>Alcohol</i> , 2017, 60, 233.	1.7	0
57	A C9ORF72 BAC mouse model recapitulates key epigenetic perturbations of ALS/FTD. <i>Molecular Neurodegeneration</i> , 2017, 12, 46.	10.8	22
58	Dependence-induced increase of alcohol self-administration and compulsive drinking mediated by the histone methyltransferase PRDM2. <i>Molecular Psychiatry</i> , 2017, 22, 1746-1758.	7.9	47
59	Reprogramming of mPFC transcriptome and function in alcohol dependence. <i>Genes, Brain and Behavior</i> , 2017, 16, 86-100.	2.2	38
60	Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer. <i>Oncogene</i> , 2017, 36, 1707-1720.	5.9	126
61	shinyheatmap: Ultra fast low memory heatmap web interface for big data genomics. <i>PLoS ONE</i> , 2017, 12, e0176334.	2.5	112
62	The BET-Bromodomain Inhibitor JQ1 Reduces Inflammation and Tau Phosphorylation at Ser396 in the Brain of the 3xTg Model of Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2016, 13, 985-995.	1.4	66
63	MicroScope: ChIP-seq and RNA-seq software analysis suite for gene expression heatmaps. <i>BMC Bioinformatics</i> , 2016, 17, 390.	2.6	13
64	Epigenomic and metabolic responses of hypothalamic POMC neurons to gestational nicotine exposure in adult offspring. <i>Genome Medicine</i> , 2016, 8, 93.	8.2	11
65	Ischemic Preconditioning Confers Epigenetic Repression of mTOR and Induction of Autophagy Through C9a-Dependent H3K9 Dimethylation. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	32
66	How the strengths of Lisp-family languages facilitate building complex and flexible bioinformatics applications. <i>Briefings in Bioinformatics</i> , 2016, 19, bbw130.	6.5	3
67	The long non-coding RNA FMR4 promotes proliferation of human neural precursor cells and epigenetic regulation of gene expression in trans. <i>Molecular and Cellular Neurosciences</i> , 2016, 74, 49-57.	2.2	37
68	Nociceptin receptor activation does not alter acquisition, expression, extinction and reinstatement of conditioned cocaine preference in mice. <i>Brain Research</i> , 2016, 1632, 34-41.	2.2	12
69	The FMR1 promoter is selectively hydroxymethylated in primary neurons of fragile X syndrome patients. <i>Human Molecular Genetics</i> , 2016, 25, ddw311.	2.9	18
70	The nociceptin/orphanin FQ receptor agonist SR-8993 as a candidate therapeutic for alcohol use disorders: validation in rat models. <i>Psychopharmacology</i> , 2016, 233, 3553-3563.	3.1	26
71	Transcriptomic Profiling of Extracellular RNAs Present in Cerebrospinal Fluid Identifies Differentially Expressed Transcripts in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2016, 6, 109-117.	2.8	40
72	Upregulation of Haploinsufficient Gene Expression in the Brain by Targeting a Long Non-coding RNA Improves Seizure Phenotype in a Model of Dravet Syndrome. <i>EBioMedicine</i> , 2016, 9, 257-277.	6.1	116

#	ARTICLE	IF	CITATIONS
73	Functional annotation of the vlinc class of non-coding RNAs using systems biology approach. <i>Nucleic Acids Research</i> , 2016, 44, 3233-3252.	14.5	31
74	Altering the course of schizophrenia: progress and perspectives. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 485-515.	46.4	410
75	C9orf72 promoter hypermethylation is reduced while hydroxymethylation is acquired during reprogramming of ALS patient cells. <i>Experimental Neurology</i> , 2016, 277, 171-177.	4.1	21
76	Changes in expression of the long non-coding RNA FMR4 associate with altered gene expression during differentiation of human neural precursor cells. <i>Frontiers in Genetics</i> , 2015, 6, 263.	2.3	22
77	Basic biology and therapeutic implications of lncRNA. <i>Advanced Drug Delivery Reviews</i> , 2015, 87, 15-24.	13.7	272
78	Bromodomain inhibitors regulate the C9ORF72 locus in ALS. <i>Experimental Neurology</i> , 2015, 271, 241-250.	4.1	25
79	Antisense RNA Controls LRP1 Sense Transcript Expression through Interaction with a Chromatin-Associated Protein, HMGB2. <i>Cell Reports</i> , 2015, 11, 967-976.	6.4	75
80	Extracellular Uridine Triphosphate and Adenosine Triphosphate Attenuate Endothelial Inflammation through miR-22-Mediated ICAM-1 Inhibition. <i>Journal of Vascular Research</i> , 2015, 52, 71-80.	1.4	27
81	Screening for Small-Molecule Modulators of Long Noncoding RNA-Protein Interactions Using AlphaScreen. <i>Journal of Biomolecular Screening</i> , 2015, 20, 1132-1141.	2.6	83
82	The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 8326-8331.	7.1	186
83	The Landscape of long noncoding RNA classification. <i>Trends in Genetics</i> , 2015, 31, 239-251.	6.7	942
84	Epigenetic Readers of Lysine Acetylation Regulate Cocaine-Induced Plasticity. <i>Journal of Neuroscience</i> , 2015, 35, 15062-15072.	3.6	66
85	Histone deacetylases (HDACs) and brain function. <i>Neuroepigenetics</i> , 2015, 1, 20-27.	2.8	128
86	A Patient-Specific Ex Vivo Screening Platform for Personalized Acute Myeloid Leukemia (AML) Therapy. <i>Blood</i> , 2015, 126, 1352-1352.	1.4	5
87	The BET Bromodomain Inhibitors EP11313 and EP11336 Have Potent Anti-Leukemic Activity in Acute Myeloid Leukemia (AML) and Augment the Effects of All-Trans-Retinoic Acid (AtRA) in Vitro. <i>Blood</i> , 2015, 126, 2552-2552.	1.4	1
88	BET bromodomain proteins are required for glioblastoma cell proliferation. <i>Epigenetics</i> , 2014, 9, 611-620.	2.7	123
89	Non-coding RNAs as direct and indirect modulators of epigenetic regulation. <i>Epigenetics</i> , 2014, 9, 3-12.	2.7	428
90	The BET Bromodomain Inhibitor I-BET151 Acts Downstream of Smoothed Protein to Abrogate the Growth of Hedgehog Protein-driven Cancers. <i>Journal of Biological Chemistry</i> , 2014, 289, 35494-35502.	3.4	102

#	ARTICLE	IF	CITATIONS
91	HeatmapGenerator: high performance RNAseq and microarray visualization software suite to examine differential gene expression levels using an R and C++ hybrid computational pipeline. Source Code for Biology and Medicine, 2014, 9, 30.	1.7	50
92	Comprehensive analysis of the transcriptional landscape of the human FMR1 gene reveals two new long noncoding RNAs differentially expressed in Fragile X syndrome and Fragile X-associated tremor/ataxia syndrome. Human Genetics, 2014, 133, 59-67.	3.8	96
93	Transcriptional repression of ER through hMAPK dependent histone deacetylation by class I HDACs. Breast Cancer Research and Treatment, 2014, 147, 249-263.	2.5	14
94	Regulation of the Apolipoprotein Gene Cluster by a Long Noncoding RNA. Cell Reports, 2014, 6, 222-230.	6.4	188
95	I-BET151 selectively regulates IL-6 production. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1549-1555.	3.8	37
96	Natural antisense transcripts. Human Molecular Genetics, 2014, 23, R54-R63.	2.9	110
97	HuD Regulates Coding and Noncoding RNA to Induce APP $\beta$ 's A $\beta$ Processing. Cell Reports, 2014, 7, 1401-1409.	6.4	90
98	Emerging treatment strategies for glioblastoma multiforme. EMBO Molecular Medicine, 2014, 6, 1359-1370.	6.9	280
99	Personalized medicine in psychiatry: problems and promises. BMC Medicine, 2013, 11, 132.	5.5	192
100	Oligonucleotides for upregulating gene expression. Pharmaceutical Patent Analyst, 2013, 2, 215-229.	1.1	6
101	Natural antisense transcripts as therapeutic targets. Drug Discovery Today: Therapeutic Strategies, 2013, 10, e119-e125.	0.5	16
102	Amygdala-Dependent Fear Is Regulated by <i>Oprl1</i> in Mice and Humans with PTSD. Science Translational Medicine, 2013, 5, 188ra73.	12.4	132
103	Platelets activated during myocardial infarction release functional miRNA, which can be taken up by endothelial cells and regulate ICAM1 expression. Blood, 2013, 121, 3908-3917.	1.4	219
104	Targeting long non-coding RNA to therapeutically upregulate gene expression. Nature Reviews Drug Discovery, 2013, 12, 433-446.	46.4	460
105	Epigenetic pathways and glioblastoma treatment. Epigenetics, 2013, 8, 785-795.	2.7	54
106	Involvement of long noncoding RNAs in diseases affecting the central nervous system. RNA Biology, 2012, 9, 860-870.	3.1	93
107	MicroRNA-132 dysregulation in schizophrenia has implications for both neurodevelopment and adult brain function. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3125-3130.	7.1	277
108	Regulation of chromatin structure by long noncoding RNAs: focus on natural antisense transcripts. Trends in Genetics, 2012, 28, 389-396.	6.7	263

#	ARTICLE	IF	CITATIONS
109	Intronic RNAs constitute the major fraction of the non-coding RNA in mammalian cells. <i>BMC Genomics</i> , 2012, 13, 504.	2.8	106
110	RNAi Joins the "Singles Club". <i>Molecular Therapy</i> , 2012, 20, 2010-2011.	8.2	2
111	The Emerging Role of Non-Coding RNAs in Drug Addiction. <i>Frontiers in Genetics</i> , 2012, 3, 106.	2.3	63
112	Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation. <i>Nature Biotechnology</i> , 2012, 30, 453-459.	17.5	575
113	Synthesis and SAR of selective small molecule neuropeptide Y Y2 receptor antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 3916-3920.	2.2	16
114	Epigenomic Implications of Antisense Transcription. <i>FASEB Journal</i> , 2012, 26, 333.4.	0.5	0
115	Knockdown of BACE1-AS Nonprotein-Coding Transcript Modulates Beta-Amyloid-Related Hippocampal Neurogenesis. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-11.	2.0	112
116	The Reality of Pervasive Transcription. <i>PLoS Biology</i> , 2011, 9, e1000625.	5.6	380
117	Role of Sirtuin 1 in metabolic regulation. <i>Drug Discovery Today</i> , 2010, 15, 781-791.	6.4	51
118	Therapeutic potential of neuropeptide Y (NPY) receptor ligands. <i>EMBO Molecular Medicine</i> , 2010, 2, 429-439.	6.9	212
119	Striatal microRNA controls cocaine intake through CREB signalling. <i>Nature</i> , 2010, 466, 197-202.	27.8	356
120	Navigating genomic maps of cancer cells. <i>Nature Biotechnology</i> , 2010, 28, 241-242.	17.5	3
121	RNAi Screen Indicates Widespread Biological Function for Human Natural Antisense Transcripts. <i>PLoS ONE</i> , 2010, 5, e13177.	2.5	35
122	Selective and Brain Penetrant Neuropeptide Y Y2 Receptor Antagonists Discovered by Whole-Cell High-Throughput Screening. <i>Molecular Pharmacology</i> , 2010, 77, 46-57.	2.3	48
123	Using molecular classification to predict gains in maximal aerobic capacity following endurance exercise training in humans. <i>Journal of Applied Physiology</i> , 2010, 108, 1487-1496.	2.5	296
124	Adult Neurogenesis: A Potential Tool for Early Diagnosis in Alzheimer's Disease?. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 395-408.	2.6	32
125	Evidence for natural antisense transcript-mediated inhibition of microRNA function. <i>Genome Biology</i> , 2010, 11, R56.	8.8	444
126	MicroRNA dysregulation in psychiatric disease. <i>Brain Research</i> , 2010, 1338, 89-99.	2.2	184



#	ARTICLE	IF	CITATIONS
127	Integration of microRNA changes in vivo identifies novel molecular features of muscle insulin resistance in type 2 diabetes. <i>Genome Medicine</i> , 2010, 2, 9.	8.2	225
128	MicroRNA-219 modulates NMDA receptor-mediated neurobehavioral dysfunction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 3507-3512.	7.1	265
129	microRNAs in CNS Disorders. <i>NeuroMolecular Medicine</i> , 2009, 11, 162-172.	3.4	73
130	The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line. <i>Nature Genetics</i> , 2009, 41, 553-562.	21.4	408
131	Regulatory roles of natural antisense transcripts. <i>Nature Reviews Molecular Cell Biology</i> , 2009, 10, 637-643.	37.0	671
132	Non-coding RNA transcripts: Sensors of neuronal stress, modulators of synaptic plasticity, and agents of change in the onset of Alzheimer's disease. <i>Neuroscience Letters</i> , 2009, 466, 81-88.	2.1	26
133	A small molecule enhances RNA interference and promotes microRNA processing. <i>Nature Biotechnology</i> , 2008, 26, 933-940.	17.5	230
134	Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of $\beta$ -secretase. <i>Nature Medicine</i> , 2008, 14, 723-730.	30.7	1,252
135	GENETIC STUDY: Association between the nociceptin receptor gene ( <i>OPRL1</i> ) single nucleotide polymorphisms and alcohol dependence. <i>Addiction Biology</i> , 2008, 13, 88-94.	2.6	34
136	Focusing on RISC assembly in mammalian cells. <i>Biochemical and Biophysical Research Communications</i> , 2008, 368, 703-708.	2.1	13
137	Analysis of siRNA specificity on targets with double-nucleotide mismatches. <i>Nucleic Acids Research</i> , 2008, 36, e53-e53.	14.5	63
138	Epigenetic mechanisms of gene regulation during mammalian spermatogenesis. <i>Epigenetics</i> , 2008, 3, 21-27.	2.7	41
139	Gene Characterization Index: Assessing the Depth of Gene Annotation. <i>PLoS ONE</i> , 2008, 3, e1440.	2.5	9
140	A Novel RNA Transcript with Antiapoptotic Function Is Silenced in Fragile X Syndrome. <i>PLoS ONE</i> , 2008, 3, e1486.	2.5	159
141	Altered regulation of the PINK1 locus: a link between type 2 diabetes and neurodegeneration?. <i>FASEB Journal</i> , 2007, 21, 3653-3665.	0.5	83
142	Myogenic gene expression signature establishes that brown and white adipocytes originate from distinct cell lineages. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 4401-4406.	7.1	637
143	Noncoding RNAs: couplers of analog and digital information in nervous system function?. <i>Trends in Neurosciences</i> , 2007, 30, 612-621.	8.6	94
144	The human PINK1 locus is regulated in vivo by a non-coding natural antisense RNA during modulation of mitochondrial function. <i>BMC Genomics</i> , 2007, 8, 74.	2.8	125

#	ARTICLE	IF	CITATIONS
145	RNA interference is not involved in natural antisense mediated regulation of gene expression in mammals. <i>Genome Biology</i> , 2006, 7, R38.	9.6	53
146	No induction of anti-viral responses in human cell lines HeLa and MCF-7 when transfecting with siRNA or siLNA. <i>Biochemical and Biophysical Research Communications</i> , 2006, 341, 1211-1217.	2.1	25
147	Expression profiling following local muscle inactivity in humans provides new perspective on diabetes-related genes. <i>Genomics</i> , 2006, 87, 165-172.	2.9	64
148	Genome-wide analysis of mammalian promoter architecture and evolution. <i>Nature Genetics</i> , 2006, 38, 626-635.	21.4	1,201
149	Natural antisense and noncoding RNA transcripts as potential drug targets. <i>Drug Discovery Today</i> , 2006, 11, 503-508.	6.4	108
150	Nonsynonymous SNPs: validation characteristics, derived allele frequency patterns, and suggestive evidence for natural selection. <i>Human Mutation</i> , 2006, 27, 173-186.	2.5	9
151	Apoptosis resistance downstream of eIF4E: posttranscriptional activation of an anti-apoptotic transcript carrying a consensus hairpin structure. <i>Nucleic Acids Research</i> , 2006, 34, 4375-4386.	14.5	61
152	Pseudo-messenger RNA: Phantoms of the Transcriptome. <i>PLoS Genetics</i> , 2006, 2, e23.	3.5	58
153	RNA Interference with Chemically Modified siRNA. <i>Current Topics in Medicinal Chemistry</i> , 2006, 6, 893-900.	2.1	41
154	Complex Loci in Human and Mouse Genomes. <i>PLoS Genetics</i> , 2006, 2, e47.	3.5	290
155	A Novel Single Nucleotide Polymorphism of the Neuropeptide Y (NPY) Gene Associated With Alcohol Dependence. <i>Alcoholism: Clinical and Experimental Research</i> , 2005, 29, 702-707.	2.4	62
156	Complex HTR2C linkage disequilibrium and promoter associations with body mass index and serum leptin. <i>Human Genetics</i> , 2005, 117, 545-557.	3.8	32
157	Human muscle gene expression responses to endurance training provide a novel perspective on Duchenne muscular dystrophy. <i>FASEB Journal</i> , 2005, 19, 750-760.	0.5	128
158	A systematic analysis of the silencing effects of an active siRNA at all single-nucleotide mismatched target sites. <i>Nucleic Acids Research</i> , 2005, 33, 1671-1677.	14.5	205
159	A universal plasmid library encoding all permutations of small interfering RNA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 2356-2361.	7.1	40
160	Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. <i>Nucleic Acids Research</i> , 2005, 33, 439-447.	14.5	472
161	Human neuropeptide Y signal peptide gain-of-function polymorphism is associated with increased body mass index: possible mode of function. <i>Regulatory Peptides</i> , 2005, 127, 45-53.	1.9	71
162	Kinetics of Senescence-associated Changes of Gene Expression in an Epithelial, Temperature-sensitive SV40 Large T Antigen Model. <i>Cancer Research</i> , 2004, 64, 482-489.	0.9	24

#	ARTICLE	IF	CITATIONS
163	ANALYSIS OF 5-HYDROXYTRYPTAMINE 2C RECEPTOR GENE PROMOTER VARIANTS AS ALCOHOL-DEPENDENCE RISK FACTORS. <i>Alcohol and Alcoholism</i> , 2004, 39, 380-385.	1.6	9
164	Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism. <i>Journal of Psychiatric Research</i> , 2004, 38, 113-121.	3.1	161
165	Exploring the Foundation of Genomics: A Northern Blot Reference set for the Comparative Analysis of Transcript Profiling Technologies. <i>Comparative and Functional Genomics</i> , 2004, 5, 584-595.	2.0	2
166	Genetics of neurological disorders. <i>Expert Review of Molecular Diagnostics</i> , 2004, 4, 317-332.	3.1	17
167	Locked nucleic acid containing antisense oligonucleotides enhance inhibition of HIV-1 genome dimerization and inhibit virus replication. <i>FEBS Letters</i> , 2004, 578, 285-290.	2.8	30
168	Functional comparison of single- and double-stranded siRNAs in mammalian cells. <i>Biochemical and Biophysical Research Communications</i> , 2004, 316, 680-687.	2.1	25
169	Characterization of RNA interference in rat PC12 cells: requirement of GERp95. <i>Biochemical and Biophysical Research Communications</i> , 2004, 318, 927-934.	2.1	10
170	Improved and automated prediction of effective siRNA. <i>Biochemical and Biophysical Research Communications</i> , 2004, 319, 264-274.	2.1	129
171	Validating siRNA using a reporter made from synthetic DNA oligonucleotides. <i>Biochemical and Biophysical Research Communications</i> , 2004, 325, 243-249.	2.1	35
172	Activity-induced and developmental downregulation of the Nogo receptor. <i>Cell and Tissue Research</i> , 2003, 311, 333-342.	2.9	71
173	Anti-cataleptic effects of clozapine, but not olanzapine and quetiapine, on SCH 23390- or raclopride-induced catalepsy in rats. <i>European Neuropsychopharmacology</i> , 2003, 13, 177-182.	0.7	6
174	Effective small interfering RNAs and phosphorothioate antisense DNAs have different preferences for target sites in the luciferase mRNAs. <i>Biochemical and Biophysical Research Communications</i> , 2003, 306, 712-717.	2.1	60
175	Behavioural analysis of melanin-concentrating hormone in rats: evidence for orexigenic and anxiolytic properties. <i>Regulatory Peptides</i> , 2003, 114, 109-114.	1.9	55
176	GeneLynx Mouse: Integrated Portal to the Mouse Genome. <i>Genome Research</i> , 2003, 13, 1501-1504.	5.5	13
177	Small GTP-Binding Protein Rac Is an Essential Mediator of Vascular Endothelial Growth Factor-Induced Endothelial Fenestrations and Vascular Permeability. <i>Circulation</i> , 2003, 107, 1532-1538.	1.6	110
178	mRNA accessible site tagging (MAST): a novel high throughput method for selecting effective antisense oligonucleotides. <i>Nucleic Acids Research</i> , 2003, 31, 72e-72.	14.5	32
179	NPY Leu7Pro and alcohol dependence in Finnish and Swedish populations. <i>Alcoholism: Clinical and Experimental Research</i> , 2003, 27, 19-24.	2.4	21
180	Quantitative codon optimisation of DNA libraries encoding sub-random peptides: design and characterisation of a novel library encoding transmembrane domain peptides. <i>Nucleic Acids Research</i> , 2002, 30, 133e-133.	14.5	2

#	ARTICLE	IF	CITATIONS
181	NotI subtraction and NotI-specific microarrays to detect copy number and methylation changes in whole genomes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 10724-10729.	7.1	54
182	NotI flanking sequences: a tool for gene discovery and verification of the human genome. <i>Nucleic Acids Research</i> , 2002, 30, 3163-3170.	14.5	20
183	hUNC93B1: a novel human gene representing a new gene family and encoding an unc-93-like protein. <i>Gene</i> , 2002, 283, 209-217.	2.2	30
184	Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 2344-2349.	7.1	1,126
185	Initial isolation and analysis of the human Kv1.7 ( KCNA7 ) gene, a member of the voltage-gated potassium channel gene family. <i>Gene</i> , 2001, 268, 115-122.	2.2	10
186	A two-dimensional protein map of <i>Caenorhabditis elegans</i> . <i>Electrophoresis</i> , 2001, 22, 1224-1232.	2.4	32
187	A novel method using baculovirus-mediated gene transfer for production of recombinant adeno-associated virus vectors. <i>Journal of General Virology</i> , 2001, 82, 2051-2060.	2.9	42
188	Isolation and chromosomal localization of a new human retinoblastoma binding protein 2 homologue 1a (RBBP2H1A). <i>European Journal of Human Genetics</i> , 2000, 8, 407-413.	2.8	14
189	CIS-cloning of identical sequences between two complex genomes. <i>Chromosome Research</i> , 2000, 8, 77-84.	2.2	5
190	Antisense Inhibition of $\mu$ -Opioid Receptor Gene Function In Vivo by Peptide Nucleic Acids. <i>Molecular Pharmacology</i> , 2000, 57, 725-731.	2.3	56
191	A Visual Intracellular Classification Strategy for Uncharacterized Human Proteins. <i>Experimental Cell Research</i> , 2000, 259, 239-246.	2.6	15
192	Isolation of sex-specific cDNAs from fetal mouse brain using mRNA differential display and representational difference analysis. <i>Molecular Brain Research</i> , 1999, 74, 91-97.	2.3	6
193	FUNCTIONAL PSYCHOGENOMICS. <i>Behavioural Pharmacology</i> , 1999, 10, S98.	1.7	0
194	Cloning and Evaluation of the Role of Rat GALR-2, a Novel Subtype of Galanin Receptor, in the Control of Pain Perception. <i>Annals of the New York Academy of Sciences</i> , 1998, 863, 108-119.	3.8	26
195	Vascular Effects of Proteinase-Activated Receptor 2 Agonist Peptide. <i>Journal of Vascular Research</i> , 1997, 34, 267-272.	1.4	69
196	Novel "Restoration of Function" Mutagenesis Strategy to Identify Amino Acids of the $\mu$ -Opioid Receptor Involved in Ligand Binding. <i>Journal of Biological Chemistry</i> , 1997, 272, 9260-9267.	3.4	48
197	Effects of phosphorothioated neuropeptide Y Y1-receptor antisense oligodeoxynucleotide in conscious rats and in human vessels. <i>British Journal of Pharmacology</i> , 1996, 118, 131-136.	5.4	9
198	Neuropeptide Y receptor gene regulation in mouse adrenocortical Y-1 cells. <i>Regulatory Peptides</i> , 1996, 63, 53-56.	1.9	11

#	ARTICLE	IF	CITATIONS
199	Involvement of Trp-284, Val-296, and Val-297 of the Human $\hat{\mu}$ -Opioid Receptor in Binding of $\hat{\mu}$ -Selective Ligands. <i>Journal of Biological Chemistry</i> , 1996, 271, 18789-18796.	3.4	90
200	Characterisation of an ATP receptor mediating mitogenesis in vascular smooth muscle cells. <i>European Journal of Pharmacology</i> , 1995, 289, 135-149.	2.6	68
201	Section Review: Biologicals & Immunologicals: Applications of antisense technology to both basic and clinical research. <i>Expert Opinion on Investigational Drugs</i> , 1995, 4, 637-646.	4.1	3
202	Effects of Some Novel D-myo-Inositol-Phosphate Derivatives on Binding and Sympathetic Transmission. <i>Journal of Cardiovascular Pharmacology</i> , 1995, 25, 696-704.	1.9	5
203	Cellular uptake of intracerebroventricularly administered biotin- or digoxigenin-Labeled antisense oligodeoxynucleotides in the rat. <i>Cellular and Molecular Neurobiology</i> , 1994, 14, 475-486.	3.3	58
204	Characterization of specific binding sites for $\hat{\mu}$ -trinositol (d-myo-inositol 1,2,6-trisphosphate) in rat tissues. <i>European Journal of Pharmacology</i> , 1994, 268, 55-63.	2.6	26
205	Hypothalamic neuropeptide Y, its gene expression and receptor activity: relation to circulating corticosterone in adrenalectomized rats. <i>Brain Research</i> , 1994, 665, 201-212.	2.2	84
206	Antisense oligonucleotide strategies in neuropharmacology. <i>Trends in Pharmacological Sciences</i> , 1994, 15, 42-46.	8.7	265
207	Specific inhibition of endogenous neuropeptide Y synthesis in arcuate nucleus by antisense oligonucleotides suppresses feeding behavior and insulin secretion. <i>Molecular Brain Research</i> , 1994, 21, 55-61.	2.3	176
208	Modulation of vascular function by neuropeptide Y during development of hypertension in spontaneously hypertensive rats. <i>Pediatric Nephrology</i> , 1993, 7, 845-852.	1.7	33
209	Quantitation of NMDA receptor (NMDAR1) mRNA levels in the adult and developing rat CNS. <i>Molecular Brain Research</i> , 1993, 19, 93-100.	2.3	50
210	A proposed bovine neuropeptide Y (NPY) receptor cDNA clone, or its human homologue, confers neither NPY binding sites nor NPY responsiveness on transfected cells. <i>Regulatory Peptides</i> , 1993, 47, 247-258.	1.9	89
211	Neuropeptide Y suppresses the neurogenic inflammatory response in the rabbit eye; mode of action. <i>Regulatory Peptides</i> , 1993, 43, 57-64.	1.9	13
212	Mitogenic effect of neuropeptide Y in rat vascular smooth muscle cells. <i>Peptides</i> , 1993, 14, 263-268.	2.4	112
213	Characterization of vascular neuropeptide Y receptors. <i>British Journal of Pharmacology</i> , 1992, 105, 45-50.	5.4	115
214	Identification of cultured cells selectively expressing Y1-, Y2-, or Y3-type receptors for neuropeptide Y/peptide YY. <i>Life Sciences</i> , 1992, 50, PL7-PL12.	4.3	158
215	Specific binding of inositol hexakisphosphate (phytic acid) to adrenal chromaffin cell membranes and effects on calcium-dependent catecholamine release. <i>Biochemical Pharmacology</i> , 1992, 43, 1331-1336.	4.4	22
216	Receptor-selective analogs demonstrate NPY/PYY receptor heterogeneity in rat brain. <i>Neuroscience Letters</i> , 1991, 130, 32-36.	2.1	83

#	ARTICLE	IF	CITATIONS
217	Long-lasting inhibition of the cardiovascular responses to glutamate and the baroreceptor reflex elicited by neuropeptide Y injected into the nucleus tractus solitarius of the rat. <i>Neuroscience Letters</i> , 1991, 122, 135-139.	2.1	55
218	Strategies to Detect Heterologously Expressed Tachykinin Receptors in <i>Xenopus</i> Oocytes. <i>Annals of the New York Academy of Sciences</i> , 1991, 632, 116-122.	3.8	1
219	Neuropeptide Y Receptor Subtypes, Y1 and Y2. <i>Annals of the New York Academy of Sciences</i> , 1990, 611, 7-26.	3.8	223
220	High Doses of Neuropeptide Y Reduce Blood Pressure in Anesthetized Rats. <i>Annals of the New York Academy of Sciences</i> , 1990, 611, 415-417.	3.8	0
221	Electroconvulsive shocks increase the concentration of neocortical and hippocampal neuropeptide Y (NPY)-like immunoreactivity in the rat. <i>Brain Research</i> , 1990, 507, 65-68.	2.2	112
222	Neuropeptide Y (NPY) and the central nervous system: Distribution effects and possible relationship to neurological and psychiatric disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1989, 13, 31-54.	4.8	77
223	Neuropeptide Y (NPY)-induced suppression of activity in the rat: evidence for NPY receptor heterogeneity and for interaction with $\hat{1}\pm$ -adrenoceptors. <i>European Journal of Pharmacology</i> , 1988, 157, 205-213.	3.5	103
224	Neuropeptide Y (NPY) in the area of the hypothalamic paraventricular nucleus activates the pituitary-adrenocortical axis in the rat. <i>Brain Research</i> , 1987, 417, 33-38.	2.2	284
225	Hirschsprung's disease: A comparison of the nervous control of ganglionic and aganglionic smooth muscle in vitro. <i>Journal of Pediatric Surgery</i> , 1987, 22, 431-435.	1.6	18
226	Calcitonin gene-related peptide in the eye: release by sensory nerve stimulation and effects associated with neurogenic inflammation. <i>Regulatory Peptides</i> , 1986, 16, 107-115.	1.9	128
227	Evidence for different pre- and post-junctional receptors for neuropeptide Y and related peptides. <i>Regulatory Peptides</i> , 1986, 13, 307-318.	1.9	610
228	Is histamine a neurotransmitter in the gut? Evidence from histidine decarboxylase immunocytochemistry. <i>Acta Physiologica Scandinavica</i> , 1985, 123, 225-227.	2.2	11
229	Neuropeptide Y potentiates the effect of various vasoconstrictor agents on rabbit blood vessels. <i>British Journal of Pharmacology</i> , 1984, 83, 519-525.	5.4	377
230	Supersensitivity to substance P and physalaemin in rat salivary glands after denervation or decentralization. <i>Acta Physiologica Scandinavica</i> , 1982, 115, 437-446.	2.2	67
231	PLX51107, a promising novel bromodomain and extra-terminal inhibitor in chronic lymphoid leukemia treatment. <i>Precision Cancer Medicine</i> , 0, 1, 14-14.	1.8	0
232	Molecular Transducers of Human Skeletal Muscle Remodeling Under Different Loading States. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
233	Optimized functional annotation of ChIP-seq data. <i>F1000Research</i> , 0, 8, 612.	1.6	0